LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healthcare MedTech ...

In the latest market close, AngioDynamics (ANGO) reached $5.99, with a +1.7% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 2.11%. Elsewhere, the Dow gained 1.18%, while the tech-heavy Nasdaq added 2.96%.The the stock of medical device maker has fallen by 1.83% in the past month, lagging the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.The investment community will be closely monitoring the performance of AngioDynamics in its forthcoming ...

AngioDynamics, Inc. (ANGO) recently announced the completion of the sale of its PICC and Midline product portfolios to Spectrum Vascular for $45 million in cash.AngioDynamics' PICC, Midline, and tip location products are the subject of the transaction. During AngioDynamics' fiscal 2023, the combined portfolio of products contributed more than $43.5 million in revenues annually.Price PerformanceFor the past six months, ANGO’s shares have declined 28.1% against the industry’s rise of 7.8%. The S&P 500 increas ...

AngioDynamics (ANGO) closed the latest trading day at $6.17, indicating a +1.31% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily gain of 0.58%. Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 0.3%.Coming into today, shares of the medical device maker had gained 3.4% in the past month. In that same time, the Medical sector gained 2.39%, while the S&P 500 gained 4.61%.Investors will be eagerly watching for the performance of AngioDynamics in ...

In the latest market close, AngioDynamics (ANGO) reached $6.09, with a -0.98% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.57% for the day. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 1.25%.The medical device maker's shares have seen an increase of 1.49% over the last month, not keeping up with the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07%.The upcoming earnings release of AngioDynamic ...

AngioDynamics, Inc. (ANGO) recently announced the US Food and Drug Administration (FDA) clearance for the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD).With this 225-cm catheter length, access points in Atherectomy procedures can be expanded, which can help reduce access site complications and accelerate patient recovery.Price PerformanceFor the past six months, ANGO’s shares have plunged 31.0% compared w ...

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 5 cents for second-quarter fiscal 2024, against the year-ago earnings per share (EPS) of a penny. However, the adjusted loss per share was narrower than the Zacks Consensus Estimate of a loss of 9 cents per share.Excluding Dialysis and BioSentry, on a pro-forma basis, adjusted loss per share in second-quarter fiscal 2024 was also 5 cents, narrower than the adjusted loss per share of 9 cents in the year-ago period.GAAP loss per share was 72 ce ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioD ...

Financial Data and Key Metrics Changes - Revenue for Q2 FY 2024 was $79.1 million, representing a year-over-year growth of approximately 3% [8][19] - Adjusted EPS was a loss of $0.05, an improvement from a loss of $0.09 in the same quarter last year [26] - Gross margin for Q2 FY 2024 was 50.9%, a decrease of 80 basis points compared to the prior year [22][23] Business Line Data and Key Metrics Changes - Med Tech revenue was $25.4 million, a 3.5% year-over-year increase, while Med Device revenue was $53.7 million, growing 2.3% [19] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, declined 4.7% year-over-year [20] - NanoKnife sales grew approximately 2.8% during the quarter, with total NanoKnife sales up 16.7% year-to-date [12][21] Market Data and Key Metrics Changes - International business grew 12.6% year-over-year, with double-digit growth from both Med Tech and Med Device segments [14] - The U.S. market saw a decline in probe sales for NanoKnife, while capital sales grew robustly by 22.8% [21] Company Strategy and Development Direction - The company is transitioning to a fully outsourced manufacturing model, expected to drive annualized savings of approximately $15 million by FY 2027 [15][16] - Focus remains on portfolio optimization and driving growth in both Med Tech and Med Device businesses [7][18] - Anticipated product launches and regulatory approvals are set to open larger, high-growth markets [17][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds in the thrombectomy business but remains optimistic about future growth driven by new product introductions and regulatory approvals [9][37] - The company expects FY 2024 revenue to be in the range of $320 million to $325 million, down from previous guidance [27] - Management emphasized the importance of training and preparing sales teams for upcoming product launches and market expansions [38][39] Other Important Information - Research and development expenses increased to $8.7 million, representing 10.9% of sales, compared to 8.8% of sales a year ago [25] - The company has zero debt on the balance sheet and cash and cash equivalents increased to $60.9 million [26] Q&A Session Summary Question: Will gross margin continue to decrease until the shift to third-party manufacturing is complete? - Management indicated that while there may be fluctuations, the most significant benefits will come at the end of the two-year transition period [33][34] Question: What factors are expected to drive sales increases in thrombectomy? - Management highlighted the breakthrough designation for AngioVac and anticipated FDA approvals as key drivers for future sales growth [36][37] Question: Can you elaborate on the headwinds faced by AngioVac? - Management noted that AngioVac serves a smaller market and emphasized the importance of new sales leadership and training to address challenges [41][42] Question: What improvements are expected with AlphaVac 2? - Management discussed unique design elements of AlphaVac that enhance usability and safety, with pricing positioned competitively in the market [44][46] Question: What is the logistical process for moving to a fully outsourced model? - Management explained that the transition will occur over two years, with established protocols and supplier partnerships already in place [55][56]

AngioDynamics Second Quarter 2024 Earnings Presentation Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of ...